Biotricity Inc.(BTCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BTCY Biotricity Inc.

Closed 07-14 16:00:00 EDT Delay

{"stockData":{"symbol":"BTCY","market":"US","secType":"STK","nameCN":"Biotricity Inc.","latestPrice":0.09919,"timestamp":1784059200000,"preClose":0.121254,"halted":0,"volume":17121,"delay":15,"changeRate":-0.18196513104722317,"floatShares":16716279,"shares":28597300,"eps":-0.175743,"marketStatus":"Closed","change":-0.022064,"latestTime":"07-14 16:00:00 EDT Delay","open":0.12369,"high":0.12369,"low":0.09919,"amount":1954.241064,"amplitude":0.202055,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.175743,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1784102400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1629950400000,"exchange":"OTCQB","adjPreClose":0.121254,"volumeRatio":0.244822},"requestUrl":"/m/hq/s/BTCY/","defaultTab":"news","newsList":[{"id":"2651484350","title":"Biotricity FY26 Net Loss Narrows to $3.13 Million; Revenue Rises 16% to $16 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2651484350","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651484350?lang=en_us&edition=fundamental","pubTime":"2026-07-15 05:26","pubTimestamp":1784064369,"startTime":"0","endTime":"0","summary":"Biotricity FY26 net loss narrows to $3.13 million; revenue rises 16% to $16 millionBiotricity reported fiscal 2026 net loss attributable to common stockholders of USD 3.13 million, narrowing from USD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nNDLGcNRf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTCY","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647789753","title":"Biotricity Delays Annual Report Filing for Year Ended March 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2647789753","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647789753?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:08","pubTimestamp":1782727698,"startTime":"0","endTime":"0","summary":"Biotricity delays annual report filing for year ended March 31, 2026Biotricity filed a Form 12b-25 to delay its Form 10-K for the fiscal year ended March 31, 2026.The filing cited time constraints tie","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL9V1bbl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","BTCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643755339","title":"Biotricity shareholders back 100-for-1 reverse stock split","url":"https://stock-news.laohu8.com/highlight/detail?id=2643755339","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643755339?lang=en_us&edition=fundamental","pubTime":"2026-06-16 18:03","pubTimestamp":1781604232,"startTime":"0","endTime":"0","summary":"Biotricity’s board and consenting shareholders executed a joint written consent dated May 28, 2026 to move ahead with a reverse stock split.The action authorizes a 100-for-1 reverse split of issued and outstanding common stock, targeted for implementation within 10 days of FINRA notice.Fractional shares will be rounded up to the nearest whole share, with no cash paid for fractional interests.The board retained discretion to abandon the reverse split if it later determines the transaction is no longer in shareholders’ best interests.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biotricity Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL6NK6bb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","BTCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639244672","title":"Biotricity files draft information statement with SEC","url":"https://stock-news.laohu8.com/highlight/detail?id=2639244672","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639244672?lang=en_us&edition=fundamental","pubTime":"2026-05-30 04:07","pubTimestamp":1780085233,"startTime":"0","endTime":"0","summary":"Biotricity shareholders authorized a 100-for-1 reverse stock split of the company’s common stock.Each 100 shares outstanding on the effective date will convert into 1 share, with fractional shares rounded up to whole shares.The reverse split would not change the number of authorized common shares.Implementation is targeted for no later than 10 days after notifying FINRA, with the board retaining discretion to proceed or not.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biotricity Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2026, and is solely responsible for the informa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL8hFfNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","BTCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634211928","title":"Biotricity to present at LD Micro Invitational XVI","url":"https://stock-news.laohu8.com/highlight/detail?id=2634211928","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634211928?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:41","pubTimestamp":1778589707,"startTime":"0","endTime":"0","summary":"Biotricity scheduled to present at LD Micro Invitational XVI on May 18, 2026 at 12:30 PM PDT in Los Angeles.Conference runs May 18-19, 2026 at Luxe Sunset Boulevard Hotel.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biotricity Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDLbFgkX7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","BTCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632838625","title":"Biotricity Restructures Capital via New Series C Preferred","url":"https://stock-news.laohu8.com/highlight/detail?id=2632838625","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632838625?lang=en_us&edition=fundamental","pubTime":"2026-05-02 06:32","pubTimestamp":1777674779,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Biotricity ( ($BTCY) ). On May 1, 2026, Biotricity Inc. entered into exchange agreements with holders of more t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biotricity-restructures-capital-via-new-series-c-preferred?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biotricity-restructures-capital-via-new-series-c-preferred?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BTCY","BK4585","BK4588","BK4594","BK4601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632970628","title":"Biotricity issues 1,957,297 Series C preferred shares in unregistered exchange offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2632970628","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632970628?lang=en_us&edition=fundamental","pubTime":"2026-05-02 05:29","pubTimestamp":1777670946,"startTime":"0","endTime":"0","summary":"Biotricity completed an unregistered exchange on May 1, 2026, issuing 1,957,297 shares of newly created Series C Preferred Stock.Exchange covered 14,144,325 common shares, options for 3,992,427 common shares, warrants for 1,436,216 common shares.Series C Preferred Stock carries 40 votes per share.Series C automatically converts upon a Qualified Financing of at least $15 million into 59.6% of outstanding common stock.Conversion right shifts on March 31, 2028, allowing holders to convert each Series C share into 10 common shares if no Qualified Financing occurs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biotricity Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDLVhcQy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","BTCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612942782","title":"Biotricity Q3 FY2026 gross margin rises 81.5% (+5.1%)","url":"https://stock-news.laohu8.com/highlight/detail?id=2612942782","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612942782?lang=en_us&edition=fundamental","pubTime":"2026-02-19 06:31","pubTimestamp":1771453915,"startTime":"0","endTime":"0","summary":"Biotricity reported Q3 FY2026 results  with revenue of USD 4 million  and gross margin of 81.5%. Net loss narrowed to USD 1.1 million, or USD 0.042 per share. Recurring  Technology Fees rose to USD 3.6 million  and represented 91.2% of Q3 FY2026 revenue. The company cited 90+% customer retention, app users scaling to more than 44,000 from 4,500 over two years, and a network of over 2,500 providers supporting 4,000,000 patients annually. Biotricity also said it is on track to obtain FDA clearance for its AI clinical model in the coming months and noted international approvals in Canada, Saudi Arabia, and Argentina.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biotricity Inc. published the original content used to generate this news br","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL74Zpwq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","BTCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610962615","title":"Biotricity Q3 EPS $(0.04) Beats $(0.08) Estimate, Sales $3.988M Miss $4.100M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2610962615","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610962615?lang=en_us&edition=fundamental","pubTime":"2026-02-12 06:27","pubTimestamp":1770848851,"startTime":"0","endTime":"0","summary":"Biotricity (OTC:BTCY) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.08) by 47.5 percent. This is a 740 percent decrease over losses of $(0.01) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50563961/biotricity-q3-eps-0-04-beats-0-08-estimate-sales-3-988m-miss-4-100m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Biotricity Q3 EPS $(0.04) Beats $(0.08) Estimate, Sales $3.988M Miss $4.100M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTCY","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610692149","title":"Biotricity Inc. Q3 EBITDA rises nearly fivefold to USD 0.67 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2610692149","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610692149?lang=en_us&edition=fundamental","pubTime":"2026-02-12 05:30","pubTimestamp":1770845403,"startTime":"0","endTime":"0","summary":"Biotricity Inc. released its quarterly earnings report for the period ending December 31, 2025. The company reported improved EBITDA and adjusted EBITDA for both the three- and nine-month periods ended December 31, 2025, with EBITDA increasing by nearly fivefold and adjusted EBITDA rising by over double. Management highlighted that these improvements are attributed to the company's focus on core operating activities, excluding non-cash items like share-based compensation and discretionary preferred stock dividend payments. Additionally, Biotricity reported a translation adjustment loss of 15 thousand for the quarter, compared to a loss of 77 thousand in the same period of the previous year. The company, which specializes in biometric data monitoring solutions for medical and healthcare markets, reaffirmed its commitment to delivering remote monitoring solutions focused on diagnostic and post-diagnostic care for lifestyle and chronic illnesses. However, management noted the existence of","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL3tLzB7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","BTCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610965451","title":"Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding Ebitda","url":"https://stock-news.laohu8.com/highlight/detail?id=2610965451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610965451?lang=en_us&edition=fundamental","pubTime":"2026-02-12 05:00","pubTimestamp":1770843601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA9NGKSV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BTCY","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609584732","title":"Biotricity Inc. announces upcoming third quarter financial results and business update call","url":"https://stock-news.laohu8.com/highlight/detail?id=2609584732","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609584732?lang=en_us&edition=fundamental","pubTime":"2026-02-06 05:15","pubTimestamp":1770326134,"startTime":"0","endTime":"0","summary":"Biotricity Inc. will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11, 2026, at 4:30 PM ET. The results will be released during the call, which can be accessed via the webcast URL. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks, followed by a Q&A session for investors. A replay will be available in the Investors section of the Biotricity website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biotricity Inc. published the original content used to generate this news brief via GlobeNewswire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL2T2cb6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014013.SGD","NDAQ","SG9999014039.USD","BTCY","BK4112","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","BK4585","IE00BGHQF748.EUR","LU2210149790.SGD","BK4167","BK4588","SG9999014005.SGD","SG9999014021.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biotricity.com","stockEarnings":[{"period":"1week","weight":0.0364},{"period":"1month","weight":-0.0339},{"period":"3month","weight":-0.0339},{"period":"6month","weight":-0.3372},{"period":"1year","weight":-0.6225},{"period":"ytd","weight":0.1875}],"description":"Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.","exchange":"OTCQB","name":"Biotricity Inc.","nameEN":"Biotricity Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biotricity Inc.(BTCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biotricity Inc.(BTCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biotricity Inc.,BTCY,Biotricity Inc.股票,Biotricity Inc.股票老虎,Biotricity Inc.股票老虎国际,Biotricity Inc.行情,Biotricity Inc.股票行情,Biotricity Inc.股价,Biotricity Inc.股市,Biotricity Inc.股票价格,Biotricity Inc.股票交易,Biotricity Inc.股票购买,Biotricity Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biotricity Inc.(BTCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biotricity Inc.(BTCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction